Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone

    loading  Checking for direct PDF access through Ovid

Abstract

Zoledronic acid has been the standard of care for the prevention of skeletal-related events in patients with bone metastases from prostate cancer for the past 10 years. However, its potent antitumor activity has been questioned. We report the occurrence of a complete clinical and biological response to zoledronic acid in a patient with bone metastases from castrate-resistant prostate cancer.

Related Topics

    loading  Loading Related Articles